Overview

City Therapeutics develops RNA interference (RNAi) medicines. It works on creating next-generation trigger molecules and delivery ligands to silence disease-causing genes in the body. The core product approach uses RNAi to turn off specific genes in cells, reducing the production of harmful proteins. Delivery and targeting are tailored, so the RNAi triggers reach the right tissues more effectively than before. Compared with peers, City Therapeutics emphasizes proprietary trigger chemistry and ligand-based delivery to improve precision and expand the range of diseases that can be treated, aiming for strong therapeutic impact rather than relying on traditional small molecules or antibodies. The company’s goal is to advance and apply RNAi-based medicines across multiple conditions by leveraging human genetics insights, partnerships, and focused development to bring effective gene-silencing therapies to patients.

Simplify's Take

What believers are saying

• Biogen CNS partnership yields $16M upfront and $1B milestones.
• CITY-FXI Phase 1 trial yields data late 2026 for thromboembolism.
• $135M Series A funds pipeline through 2026 IND cadence.

What critics are saying

• Alnylam erodes edge with superior GalNAc siRNAs in 12-24 months.
• Silence SLN360 Phase 2 captures Factor XI market in 18-24 months.
• Cash burns $135M by mid-2027 without Series B funding.

What makes City Therapeutics unique

• Next-generation cityRNA triggers enable extra-hepatic tissue targeting beyond liver.
• Co-founded by Alnylam veterans like John Maraganore for RNAi expertise.
• Proprietary siRNA engineering expands RNAi to CNS and rare diseases.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$135M

Above

Industry Average

Funded Over

1 Rounds

$135,000,000

Series A

Oct 2024

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.

Series A Funding Comparison

Above Average

Industry standards

Ind Avg. $15M

$3.7M

$5M

$8.2M

$15M

$30M

$135M